RxDoctor Payments Data

Chasidy Singleton, MD

Ophthalmology · Lake City, FLNPI 1255425260

Payments from drug & device makers

$7,318in general payments, 2019–2025

Across 243 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$2K
  • AbbVie$1K
  • Alcon$701
  • Sun Pharmaceutical Industries Inc.$547
  • Sight Sciences, Inc.$416
  • Aerie Pharmaceuticals, Inc.$305
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$7,23399%
  • Education$401%
  • Gifts$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,318 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$221,639
Medicare patients
364
Services billed
1,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine64$53,866
Prednisolone Acetate596$21,750
MoxifloxacinMoxifloxacin Hcl558$15,239
SimbrinzaBrinzolamide/Brimonidine Tart43$9,562
RhopressaNetarsudil Mesylate14$8,205
RocklatanNetarsudil Mesylat/Latanoprost17$7,459
Cyclosporine12$7,123
LumiganBimatoprost15$6,717
Loteprednol Etabonate25$3,494
Latanoprost258$2,222
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat135$1,962
Fluorometholone22$1,521
Tobramycin-DexamethasoneTobramycin/Dexamethasone31$1,448
Brimonidine Tartrate132$1,199
Timolol Maleate27$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,008$60,58379 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$305$15,66431 claims
AlconSimbrinza$701$9,56243 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$76$3,49425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Lake City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →